Index

ACTH 85, 118, 126–7
activin 60
  characterization 195–8
  paracrine actions 209–12
  during pregnancy 214–17
  structure 193–5
amenorrhoea 113–41
  lactational 124–15
amniotic fluid 321–2, 344
angiogenesis 11–12
anticoagulant rodenticides 282–91
anti-oncogene 7–9, 22–3
athletes
  body composition 121
  menstrual dysfunction 113–41
  stress 122–3
  see also exercise

bait aversion 280, 298–300
basal body temperature 85
birds, spermatogenesis 233–64
blastocyst, *see* embryo
blood–testis barrier 235–7
bonding, mother–young 311–64

c-erb-A 21
c-erb-B 14–16
c-fms 17, 64–5
  ligand 12–13
c-int 10–12
c-kit 65
c-ras 21–2
c-sis 9–10
catecholoestrogen, *see* oestrogen
cell cycle 9
cervix
  effects of prostaglandins 157–8
  effects of relaxin 151–8, 166–71
α-chlorohydrin 297–8
chemosterilant 294–301
cholecystokinin 340
collagen
  effects of relaxin 151–8, 166–71
colony-stimulating factor-1 12–13, 63–7, 89–90
  in embryos 64–5, 89–90
  properties 63–4
  receptor 17, 64–5, 90
control methods, for rodent populations
  biological 274–6
  chemical 278–301
  ecological 276
  genetical 277
  mechanical 273–4
corpus luteum
  secretion of inhibin 200–9, 213
  see also luteolysis
corticotrophin-releasing hormone 118, 126–7, 319–20
CRH, *see* corticotrophin-releasing hormone
CSF-1, *see* colony-stimulating factor
cytokine 83–111

decidua
  cytokines 83–111
  growth factors 83–111
delivery 148–51, 165
  see also parturition
diet
  of athletes 120
  effects in animals 127–8
  effects in men 127–8
  effects on gonadotrophin release 128–9
  effects on oestrogen metabolism 129–31
  food preferences 348–9
  and menstrual dysfunction 113–41
  mineral deficiency 120, 124
  of Third World women 123–4

early pregnancy factor 97–8
embryo
  cytokines 83–111
  growth factors 43–71
energy expenditure
  balance 125–6, 128–9
  in sport 119–20
  in work 124
EPF, *see* early pregnancy factor
epidermal growth factor 13–16, 54–9, 66
  properties 54–5
  receptor 13–6, 55–9
erb-B 24
ethinyl oestradiol 297–8
exercise
  energy expenditure 119–20, 124, 125–6
  and gonadotrophin secretion 113–41

and melatonin 131
and menstrual dysfunction 113–41
and oestrogen metabolism 129–31
extracellular matrix 12

FGF, *see* fibroblast growth factor
fibroblast growth factor 10–12, 60–3, 66, 95
in embryos 61–3
properties 60–1
fms 25
follicle
fluids 192–200
effects of inhibin 209–12
isolation of inhibin 192–8
secretion of inhibin 200–9
follicle-stimulating hormone
and inhibin 191–222
and menstrual cycles 113–41
fos 18–20
FSH, *see* follicle-stimulating hormone

GM-CSF, *see* granulocyte macrophage stimulating factor
GnRH, *see* gonadotrophin-releasing hormone
gonadotrophin-releasing hormone
and inhibin 191–222
and menstrual cycle dysfunction 118, 127
gossypol acetic acid 297–8
granulocyte macrophage stimulating factor 65, 67, 90–1
growth factors
in embryos 43–81
and oncogenes 1–42
receptors 3–17
in uterus 1–42, 43–81, 83–111
see also individual growth factors
growth hormone 176
guanine nucleotide binding proteins 21–2

HBGF, *see* heparin binding growth factor
heparin binding growth factor 11
hydatidiform mole 217–18
hypothalamic–pituitary axis
and adrenal 118, 122–3
and exercise 117–41
opioids 126–7
and ovary 117–8

IGF-I, IGF-II, *see* insulin-like growth factors
inhibin 60, 191–232
autocrine actions 209–12
bioassay 200
characterization 195–8
and clinical disorders 217–18
control of 212–13
during pregnancy 214–17
isolation 195–8
levels 200–9
in the male 218–20
paracrine actions 209–12
radioimmunoassay 198–9
secretion 200–9, 218–20
structure 193–5
synthesis 193–5
insulin 45–54
insulin-like growth factors 13, 45–54, 66, 95
binding proteins 47, 52
gene expression 47–52
properties 45–47
role in preimplantation embryos 52–4
interferons 91–2
interleukins 12, 65, 83–9

jun 18–20

lactation
amenorrhoea
effects of relaxin 161–2, 171–3
weaning 343–5
leukaemia inhibitory factor 65, 67, 95–6
LH, *see* luteinizing hormone
LIF, *see* leukaemia inhibitory factor
luteinizing hormone
and inhibin 191–222
in menstrual cycle 113–41
effects of relaxin 176
luteolysis 92
at parturition 148, 165
lymphocytes, and interleukins 84–9

mammary tissue, effects of relaxin 161–3, 171–3
maternal behaviour 311–64
bonding to young 341–5
experience 346
licking 338–9
olfactory preferences 322–3
onset 314–6
preparation for parturition 313–14
recognition of young 323–31
responsiveness 342–3
selectivity 323–31, 346–7
vocalizations 332, 335–7
weaning 343–5
melatonin, in exercise 131
menarche 116, 121–2
menstrual cycle
dysfunction 113–41
hormone profiles 116–17, 200–9

inhibin levels 200–9
in lactation 124–5
methyl testosterone 297–8
Mifepristone 300
milk
ejection reflex 174
intake 338
weaning 343–5
mineral deficiency 120, 124
mother–young bonding 311–64
myc 20–1, 23–4

neonate
attraction to mother 331–3
behaviour 331–41
bonding to mother 335–7, 341–5
food preferences 348–9
learning 337–41
locating teat 334–5
prenatal experience 339–40
recognition of mother 348
neu 24
nipple growth 162–3
nutrition
and menstrual cycle dysfunction 113–41
see also diet

oestrogen
during ovarian cycle 200–9
during pregnancy 143–78
metabolism 129–131
at parturition 316–20
and relaxin 143–78
and uterine growth factors 1–42
oTP-1, *see* interferons
olfaction
and maternal behaviour 321–2, 324–31
and vagino-cervical stimulation 328–31
olfactory cues 326–8
amniotic fluid 327, 335
dietary 327–8
genetically determined 326–7
in utero 339–40
memory 342–3
udder 334–5
olfactory preferences 322–3
oncogenes 1–42
discovery 3–6
growth factor receptors 13–17
growth factors 9–13
guanine nucleotide binding proteins 21–2
nomenclature 5
in retroviruses 3–4
transcription factors 17–21
and uterine function 1–42
see also proto-oncogenes, anti-oncogenes

opioids
and amenorrhoea 126–7
and neonatal learning 340
and parturition 318–20
Org 5933 299–300
ovarian failure 217
oxytocin 160, 174–5
at parturition 317–20

p53 25
PAF, *see* platelet-activating factor
parturition 316–20
preparation for 313–14
site of 347–8
PDGF, *see* platelet-derived growth factor
pheromone, rodent 281
see also olfactory cues
placenta 15–16
inhibin production 214–17
platelet-activating factor 96–7
platelet-derived growth factor 9–10, 59–60, 67, 96
in embryos 59–60
properties 59
polyamines 98–9
polycystic ovarian disease 218
population control, of rodents 265–310
prenatal experience 339–40
progesterone
during ovarian cycle 200–9
at parturition 316–20
during pregnancy 143–78
and relaxin 143–78
prolactin 317
prostaglandin E2 98, 157–8
prostaglandin $F2_{\alpha}$ 92, 98
proto-oncogenes 3–4, 63–5
functional classes 6–7

ras 24
RB 25
receptors, for growth factors 3–17, 43–81
steroid hormone 18
thyroid hormone 18, 23
relaxin 143–89
autocrine effects 173–4
central effects 174–6
chemistry 144–5
effects of antibodies 149–53, 159–63
effects
on blood pressure 175
on cervix 151–8, 166–71
on delivery 148–51, 165
on mammary tissue 161–4, 171–3
on uterine contractility 158–61, 171
on uterine growth 171

isolation 144–5
secretion, in pigs 164–5
secretion, in rats 146–8
source 144
reproductive strategy 253–5, 292–5
rodent
chemical attractants 279–82
chemical repellents 278–9
chemosterilants 294–301
pheromones 281
rodent populations, 265–310
control 265–310
damage by 265–73
and human economy 270–2
and human health 267–70
see also control methods
rodenticides 282–91
RU 486, *see* Mifepristone

seminiferous tubule 233–56
sensitive period
induction of maternal behaviour 314–16
Sertoli cells 235–7, 244
sperm
maturation 240–3
production 253–5
spermatid
development 240, 244–7
spermatocytes
primary 238, 244–7
secondary 238–40, 244–7
spermatogenesis
in birds 233–64
cellular associations 244–6
cycle of 246–7
duration 251–2
regulation 252–3
wave 248–9
spermatogonia 237–8, 244–7
renewal 249–51
spermatozoa 240–4
spermiation 240–3
stress
and menstrual dysfunction 113–41
sucking behaviour 340–2

testis
of birds 234
and inhibin production 218–20
TGF-α, *see* transforming growth factor-α
TGF-β, *see* transforming growth factor-β
TNF-α and TNF-β, *see* tumour necrosis factor
training, *see* exercise
transcription factor 17–21
transforming growth factor-α 14, 54–7, 67, 87, 93–4
transforming growth factor-β 60–3, 67, 94–5, 192, 198
in embryos 61–3
properties 60–1
in uterus 94–5
trophoblast
growth factors 43–68, 83–99
inhibin production 214
tumour necrosis factor 93
tumour suppressors 22–3

uterus
cancer 23–5
cytokines 83–111
growth factors 1–42, 43–81, 83–111
oncogenes 1–42
effects of relaxin 158–61, 171

vagino-cervical stimulation 317–20, 322–3
and olfactory recognition 328–31
vasopressin 175

weaning 343–5
Wilms' tumour 8, 22–3
WT1, *see* Wilms' tumour

JUL 2 0 1993